News

Has advertising for prostate cancer treatment gone too far?


 

References

Dr. Benjamin Davies has responded to advertising claims that recently ran in the Sunday New York Times Magazine and the New Yorker with an article in Forbes entitled “Prostate Cancer Advertising: Lies And The Damn Lies (Part 1).”

“I have a rating system for prostate cancer advertisements based on two self-evident tenets. First, cancer advertising should be scrupulously true and evidence based. Second, cancer patients are uniquely vulnerable to “hopeful” advertising (or “hopeium”) since often they face devastating odds of survival. We should all – collectively – shun advertisers that take advantage of these patients,” he wrote in the first of several articles. “I have no gripe with advertising your cancer care – just be horribly honest.”

Dr. Davies is associate professor of urology and director of the urologic oncology fellowship at the University of Pittsburgh. You can see the advertisements and read his articles here.

lnikolaides@frontlinemedcom.com

On Twitter @nikolaideslaura

Recommended Reading

Fitness attenuates systolic BP’s age-related rise
MDedge Internal Medicine
FDA panel recommends changes in testosterone indications
MDedge Internal Medicine
FDA panel recommends against approval of oral testosterone replacement therapy
MDedge Internal Medicine
Specific pattern of male baldness linked to aggressive prostate cancer
MDedge Internal Medicine
Chlamydia rate higher in blacks than in whites, Mexican-Americans
MDedge Internal Medicine
AAP issues new teen contraception and sexual health guidelines
MDedge Internal Medicine
Testosterone replacement: Medical alternative to bariatric surgery?
MDedge Internal Medicine
Variants of hypogonadism in aging men warrant different treatments
MDedge Internal Medicine
Hypofractionation, vessel-sparing RT techniques for prostate cancer yield good QOL
MDedge Internal Medicine
Adding abiraterone improves suppression of intraprostate androgens
MDedge Internal Medicine